secwatch.observer — SEC 8-K summary
======================================

Issuer:     Progyny, Inc. (PGNY)
CIK:        0001551306
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001551306-22-000038
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M
--------------------------------------------------------------------------------

- Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.
- Net income guided to $28.5-29.5M ($0.28-0.29 diluted EPS); adjusted EBITDA $124-125.5M.
- Q4 2022 revenue projected at $208.9-213.9M (64-68% growth); net income $1.5-2.5M.
- Guidance increase due to resumed shipments of Menopur, a key fertility medication, after industry-wide shortage.
- Company now serves >370 clients representing 5.4 million members as it enters 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/0001551306-22-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/pgny-20221128.htm
  HTML page:      https://secwatch.observer/filing/0001551306-22-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer